Biocon Biologics completes Integration of Viatris' Biosimilar business

The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone

CPHI & PMEC India 2023 redefines pharma landscape

South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries

Roche expands hepatitis diagnostics portfolio

Almost 300 million people globally have chronic hepatitis B

Aster to separate its India and GCC businesses to unlock value

Both the India and GCC entities will be operated by separate dedicated management teams

BrainSpec receives FDA clearance to begin using AI-backed solution for non-invasive brain chemistry measurement

First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease

Fortis Healthcare to divest Fortis Malar Hospital, Chennai to MGM Healthcare

The divestment is a part of Fortis' ongoing portfolio rationalization strategy

Fosun Pharma USA and Treehill Partners to invest in biopharma space

The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market

Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta

LTTS, NVIDIA to unveil Gen AI and software defined architecture for medical devices

This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components

Pfizer and Astellas' XTANDI approved by USFDA in earlier prostate cancer treatment setting

XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer